Integrating Psychedelics into Mental Healthcare.
About
Awakn is integrating psychedelic medicine into mainstream mental healthcare to address a US$700bn annual problem in the UK and EU.
We work across three divisions - Research, Clinics and Training.
Our scientific team is led by Prof. David Nutt and Dr. Ben Sessa.
Market Potential
Annual mental health cost to the UK & EU economies US700bn
17%
of the population affected by mental health issues annually
3%
affected by alcohol and drug addiction
5%
affected by Anxiety
6%
affected by Eating Disorders
6%
affected by Depression
Divisions
We are integrating psychedelic medicine into mainstream mental healthcare across:
Research
Our extended team have led, and are leading, clinical trials that have defined the psychedelic medicine industry, including: The Bristol-Imperial MDMA-for-Alcoholism (BIMA) study, Ketamine for reduction of Alcoholic Relapse (KARE), Pilot study of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction.
We specialise in clinical trials to help psychedelic drug development companies design clinical protocols for drug commercialisation and for not-for-profit entities interested in solving material public health issues.
Get in touch to learn more:
research@awaknlifesciences.com
Clinics
We will utilise the effects of the acute drug state induced by psychedelics alongside a course of psychotherapy to treat a range of mental health issues: Alcohol Addiction, Anxiety, Depression, and Eating Disorders.
Bristol Q1 2021 | London & Manchester 2021 | Birmingham & Brighton 2022
Get in touch to learn more:
clinics@awaknlifesciences.com
Training
With both MDMA and Psilocybin predicted to be licensed and available for prescribing by doctors by 2022 the industry is going to require hundreds of clinicians who are trained and proficient at delivery psychedelic assisted psychotherapy over the next few years.
We provide accredited in person and online training.
Get in touch to learn more:
training@awaknlifesciences.com
Scientific Advisory Team
Our pioneering team is made up of some of the leading clinical researchers, scientific minds and clinical experts in the global industry.
Prof. David Nutt
Chairman, Scientific Advisory Board
Dr. Ben Sessa
Chief Medical Officer
Prof. Celia Morgan
Advisor
Dr. Michael Mithoefer
Advisor
Ann Mithoefer, BSN
Advisor
Prof. Matthew Johnson
Advisor
Corporate Team
George Scorsis
Chairman
Anthony Tennyson
Chief Executive Officer
Jonathan Held
Chief Financial Officer
Dr. Ben Sessa
Chief Medical Officer
News
18.06.2020.
Psychedelic Medical Start-Up Awakn Life Sciences Enters the UK Market with Dr. Ben Sessa
Videos
Current treatments produce sub-optimal patient outcomes, it's time for a different approach and different methods of treatment.
Dr. Ben Sessa: TEDx
Michael Pollan: Psychedelics solve mental health crisis
Revealing the Mind: The Promise of Psychedelics
Professor David Nutt: TEDx
Contact
For all enquiries, complete the form and we’ll be in touch.
Locations
Clinic:
1 Regents Street, Bristol, BS8 4HW, United Kingdom
Main Office:
Suite 200, 366 Bay St, Toronto, Ontario, M5H 4B2, Canada